Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size

British Journal of Pharmacology
K M JohnstonM J Walker


1 The effects of pretreatment with aspirin, and of prostacyclin (PGI(2)) infusions, on responses to myocardial ischaemia and infarction produced by ligation of a coronary artery were investigated in conscious rats.2 Surgical preparation, under halothane anaesthesia, consisted of implanting exteriorized aortic and jugular cannulae, ECG leads and a polypropylene/polyethylene occluder for the left anterior descending coronary artery. Ligation of the coronary artery was performed six to nine days after surgery.3 Aspirin pretreatment consisted of 100 mg/kg given intravenously 1 or 36 h before ligation. PGI(2) infusions (10-400 ng kg(-1) min(-1), i.v.) were begun 2 min before ligation and continued for 4 h afterwards.4 ECG, blood pressure, heart rate and arrhythmias were recorded starting 30 min before, and continuing for 4 h after, ligation. Twenty-four hours after ligation, in surviving animals, the heart was removed for estimation of occluded and infarcted zones.5 Some treatments provided antiarrhythmic and other protection in the first 30 min post-ligation. By 4 and 24 h post-ligation, protective effects were lost.6 Both aspirin pretreatment and low doses of prostacyclin reduced arrhythmias occurring within 30 min of ligation. Th...Continue Reading


Sep 1, 1979·Prostaglandins and Medicine·R K DixT Lawrence
Jun 1, 1979·European Journal of Pharmacology·M L OgletreeK C Nicolaou
Jan 16, 1981·European Journal of Pharmacology·I LepránL Szekeres
Jul 1, 1980·Circulation Research·S WallensteinJ L Fleiss


Feb 17, 1993·Molecular and Cellular Biochemistry·B RietzR Jacob
Jan 1, 1991·Basic Research in Cardiology·G R Brodowicz, D R Lamb
Nov 15, 1988·European Journal of Pharmacology·R ReichhalterW Kobinger
Jan 1, 1985·Molecular Aspects of Medicine·J H BottingM J Walker
Mar 1, 1990·Journal of the American College of Cardiology·M L KnudtsonH J Duff
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·A A ShehadehT J Regan
Sep 3, 2013·Circulation. Arrhythmia and Electrophysiology·Tarvinder S DhanjalM J Curtis
Dec 18, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Ken ShinmuraRoberto Bolli
Oct 1, 1984·British Journal of Pharmacology·M J CurtisM J Walker
Jan 1, 1986·Basic Research in Cardiology·V B Fiedler, M Mardin

Related Concepts

Cardiac Depressants
Cardiac Arrhythmia
Diastolic Blood Pressure
Sinus Node Artery
Electrocardiographic Recorders
Pulse Rate
Myocardial Infarction

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.


Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.